ES2871052T3 - Inhibidores tricíclicos de la poli(ADP-ribosa)polimerasa - Google Patents
Inhibidores tricíclicos de la poli(ADP-ribosa)polimerasa Download PDFInfo
- Publication number
- ES2871052T3 ES2871052T3 ES12792550T ES12792550T ES2871052T3 ES 2871052 T3 ES2871052 T3 ES 2871052T3 ES 12792550 T ES12792550 T ES 12792550T ES 12792550 T ES12792550 T ES 12792550T ES 2871052 T3 ES2871052 T3 ES 2871052T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- unsubstituted
- oxide
- azaphosphinan
- phthalazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C1)NCCP1(*)=* Chemical compound CC(C1)NCCP1(*)=* 0.000 description 7
- KNHJLNSESCKUKI-UHFFFAOYSA-N COC(c(cc(cc1)F)c1C#Cc(cc1Br)ccc1F)=O Chemical compound COC(c(cc(cc1)F)c1C#Cc(cc1Br)ccc1F)=O KNHJLNSESCKUKI-UHFFFAOYSA-N 0.000 description 1
- BRUNIDAHRLZQOH-UHFFFAOYSA-N COC(c(cc(cc1)F)c1I)=O Chemical compound COC(c(cc(cc1)F)c1I)=O BRUNIDAHRLZQOH-UHFFFAOYSA-N 0.000 description 1
- RDXMKIOPAQRRKQ-UHFFFAOYSA-N O=C(c1c2)NN=C(Cc(cc3P4(CCN(Cc5ccccc5)CC4)=O)ccc3F)c1ccc2F Chemical compound O=C(c1c2)NN=C(Cc(cc3P4(CCN(Cc5ccccc5)CC4)=O)ccc3F)c1ccc2F RDXMKIOPAQRRKQ-UHFFFAOYSA-N 0.000 description 1
- NYSJHCBHBQAYFX-UHFFFAOYSA-N O=C1NN=C(Cc(cc2)cc(P(CC3)(CCN3C3CC3)=O)c2F)c(cc2)c1cc2F Chemical compound O=C1NN=C(Cc(cc2)cc(P(CC3)(CCN3C3CC3)=O)c2F)c(cc2)c1cc2F NYSJHCBHBQAYFX-UHFFFAOYSA-N 0.000 description 1
- LXPAEQXCSCAYJX-UHFFFAOYSA-N O=C1NN=C(Cc(cc2)cc(P3(CCN(CC(F)(F)F)CC3)=O)c2F)c2ccccc12 Chemical compound O=C1NN=C(Cc(cc2)cc(P3(CCN(CC(F)(F)F)CC3)=O)c2F)c2ccccc12 LXPAEQXCSCAYJX-UHFFFAOYSA-N 0.000 description 1
- NKWRNNXACOVHNK-UHFFFAOYSA-N O=C1NN=C(Cc(cc2Br)ccc2F)c(cc2)c1cc2F Chemical compound O=C1NN=C(Cc(cc2Br)ccc2F)c(cc2)c1cc2F NKWRNNXACOVHNK-UHFFFAOYSA-N 0.000 description 1
- KUDVXLARCFBRBX-UHFFFAOYSA-N O=C1NN=C(Cc(cc2P3(CCNCC3)=O)ccc2F)c(cc2)c1cc2F Chemical compound O=C1NN=C(Cc(cc2P3(CCNCC3)=O)ccc2F)c(cc2)c1cc2F KUDVXLARCFBRBX-UHFFFAOYSA-N 0.000 description 1
- BRATYQVOINPFFS-UHFFFAOYSA-N O=C1NN=C(Cc(cc2P3(CCNCC3)=O)ccc2F)c2ccccc12 Chemical compound O=C1NN=C(Cc(cc2P3(CCNCC3)=O)ccc2F)c2ccccc12 BRATYQVOINPFFS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161491851P | 2011-05-31 | 2011-05-31 | |
| PCT/US2012/040304 WO2012166983A1 (en) | 2011-05-31 | 2012-05-31 | Tricyclic inhibitors of poly(adp-ribose)polymerase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2871052T3 true ES2871052T3 (es) | 2021-10-28 |
Family
ID=47259874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12792550T Active ES2871052T3 (es) | 2011-05-31 | 2012-05-31 | Inhibidores tricíclicos de la poli(ADP-ribosa)polimerasa |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US20140221314A1 (https=) |
| EP (2) | EP2714703B1 (https=) |
| JP (1) | JP5960253B2 (https=) |
| CN (1) | CN103717609B (https=) |
| CA (1) | CA2875025C (https=) |
| ES (1) | ES2871052T3 (https=) |
| TW (1) | TWI577693B (https=) |
| WO (1) | WO2012166983A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI577693B (zh) | 2011-05-31 | 2017-04-11 | 江蘇康緣藥業股份有限公司 | 聚（ａｄｐ-核糖）聚合酶之三環抑制劑 |
| HUE030613T2 (en) | 2012-12-31 | 2017-05-29 | Cadila Healthcare Ltd | Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 |
| EP3298005B1 (en) | 2015-05-21 | 2024-01-24 | The Regents of The University of California | Anti-cancer compounds |
| WO2017223516A1 (en) | 2016-06-24 | 2017-12-28 | The Regents Of The University Of California | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
| WO2019194738A1 (en) * | 2018-04-05 | 2019-10-10 | Noviga Research Ab | Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer |
| AU2020328598A1 (en) | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| CN112574122B (zh) * | 2019-09-27 | 2024-05-31 | 上海天慈国际药业有限公司 | 一种奥拉帕尼关键中间体的制备方法 |
| CN114276301B (zh) * | 2020-09-27 | 2025-04-01 | 江西科睿药业有限公司 | Parp抑制剂的中间体化合物及其制备方法和应用 |
| CN112624981B (zh) * | 2021-03-09 | 2021-05-25 | 南京桦冠生物技术有限公司 | 一种2-氟-5-[(4-氧代-3h-2,3-二氮杂萘基)甲基]苯甲酸的制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4183099B2 (ja) | 1995-11-17 | 2008-11-19 | ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） | エポチロンｃおよびｄ、製造法ならびに組成物 |
| CA2273083C (en) | 1996-12-03 | 2012-09-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| JP2002536968A (ja) | 1999-01-29 | 2002-11-05 | イムクローン システムズ インコーポレイティド | Ｋｄｒに特異的な抗体およびその使用 |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| EP1187633A4 (en) | 1999-04-08 | 2005-05-11 | Arch Dev Corp | USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY |
| US7151102B2 (en) * | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| AU2003211381B9 (en) | 2002-02-19 | 2009-07-30 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| DE60335359D1 (de) | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
| US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| PL1633724T3 (pl) * | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| GB0419072D0 (en) * | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| JP2008510783A (ja) * | 2004-08-26 | 2008-04-10 | クドス ファーマシューティカルズ リミテッド | ４−ヘテロアリールメチル置換フタラジノン誘導体 |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| EP2049124A4 (en) | 2006-07-20 | 2010-02-10 | Merck & Co Inc | PHOSPHOR DERIVATIVES AS HISTONDEACETYLASE HEMMER |
| US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| ES2548353T3 (es) | 2006-12-28 | 2015-10-15 | Abbvie Inc. | Inhibidores de poli(ADP-ribosa)polimerasa |
| US20080280910A1 (en) | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| TW200900396A (en) | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US20090023727A1 (en) | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
| MX2010002749A (es) | 2007-09-14 | 2010-06-25 | Astrazeneca Ab | Derivados de ftalazinona. |
| CA2702429A1 (en) * | 2007-10-17 | 2009-04-23 | Kudos Pharmaceuticals Limited | Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one |
| EP2220073B1 (en) | 2007-11-15 | 2014-09-03 | MSD Italia S.r.l. | Pyridazinone derivatives as parp inhibitors |
| UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| MX353308B (es) * | 2008-05-21 | 2018-01-08 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| EP2438066A2 (en) * | 2009-06-05 | 2012-04-11 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES |
| EP2448409A4 (en) | 2009-07-02 | 2013-04-10 | Newgen Therapeutics Inc | PHOSPHOROUS CHINAZOLIN COMPOUNDS AND METHOD OF USE THEREOF |
| TWI577693B (zh) | 2011-05-31 | 2017-04-11 | 江蘇康緣藥業股份有限公司 | 聚（ａｄｐ-核糖）聚合酶之三環抑制劑 |
-
2012
- 2012-05-31 TW TW101119653A patent/TWI577693B/zh active
- 2012-05-31 CA CA2875025A patent/CA2875025C/en active Active
- 2012-05-31 CN CN201280024255.0A patent/CN103717609B/zh active Active
- 2012-05-31 ES ES12792550T patent/ES2871052T3/es active Active
- 2012-05-31 WO PCT/US2012/040304 patent/WO2012166983A1/en not_active Ceased
- 2012-05-31 JP JP2014513717A patent/JP5960253B2/ja active Active
- 2012-05-31 EP EP12792550.1A patent/EP2714703B1/en active Active
- 2012-05-31 EP EP21161257.7A patent/EP3925962A1/en not_active Withdrawn
- 2012-05-31 US US14/122,983 patent/US20140221314A1/en not_active Abandoned
-
2016
- 2016-04-01 US US15/089,131 patent/US20170057984A1/en not_active Abandoned
-
2017
- 2017-06-15 US US15/624,201 patent/US20180094010A1/en not_active Abandoned
-
2019
- 2019-10-28 US US16/666,307 patent/US11248013B2/en active Active
-
2022
- 2022-02-14 US US17/671,436 patent/US12612425B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11248013B2 (en) | 2022-02-15 |
| EP3925962A1 (en) | 2021-12-22 |
| CN103717609A (zh) | 2014-04-09 |
| US20230027257A1 (en) | 2023-01-26 |
| CA2875025A1 (en) | 2012-12-06 |
| JP2014516989A (ja) | 2014-07-17 |
| US20200299315A1 (en) | 2020-09-24 |
| US20140221314A1 (en) | 2014-08-07 |
| EP2714703A1 (en) | 2014-04-09 |
| TW201311713A (zh) | 2013-03-16 |
| CN103717609B (zh) | 2016-05-11 |
| US20170057984A1 (en) | 2017-03-02 |
| US12612425B2 (en) | 2026-04-28 |
| CA2875025C (en) | 2021-08-03 |
| EP2714703B1 (en) | 2021-03-10 |
| JP5960253B2 (ja) | 2016-08-02 |
| US20180094010A1 (en) | 2018-04-05 |
| EP2714703A4 (en) | 2014-12-31 |
| WO2012166983A1 (en) | 2012-12-06 |
| TWI577693B (zh) | 2017-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2871052T3 (es) | Inhibidores tricíclicos de la poli(ADP-ribosa)polimerasa | |
| CA3011189C (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
| ES2780928T3 (es) | Compuestos de espiroimidazol y su uso como inhibidores de bace | |
| WO2023062575A1 (en) | Cyclic vinyl sulfone compounds as wrn inhibitors | |
| ES2548131T3 (es) | Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida | |
| ES2660914T3 (es) | Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD | |
| UA123785C2 (uk) | Сполуки піролотриазину як інгібітори tam | |
| TW202106670A (zh) | 用於治療癌症之醯基磺醯胺 | |
| UA121036C2 (uk) | 2-(морфолін-4-іл)-1,7-нафтиридини | |
| TWI528961B (zh) | 作為聚（ａｄｐ-核糖）聚合酶（ｐａｒｐ）抑制劑之經醯胺取代之吲唑 | |
| UA123813C2 (uk) | Заміщені індазоли, способи їх одержання, фармацевтичні препарати, які їх містять, та їх застосування для одержання лікарських засобів | |
| CA2732797A1 (en) | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) | |
| JP2016523282A (ja) | スルホキシイミン置換５−フルオロ−ｎ−（ピリジン−２−イル）ピリジン−２−アミン誘導体およびそのｃｄｋ９キナーゼ阻害薬としての使用 | |
| EP3019171B1 (en) | Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4) | |
| AU2017389818B2 (en) | Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof | |
| CN118055933A (zh) | 选择性parp1抑制剂及其应用 | |
| JP2019515932A (ja) | チロシンキナーゼｂｃｒ−ａｂｌ阻害剤としての新規複素環化合物 | |
| ES2773511T3 (es) | Derivados de 1,4-dicarbonil-piperidilo | |
| JP2025535496A (ja) | 化合物及びその使用 | |
| JP2020523361A (ja) | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤、調製方法および使用 | |
| KR20260019517A (ko) | 3,4-디히드로프탈라진-1(2h)-온 유도체, 및 이의 제조 방법 및 이의 용도 | |
| JP2024534208A (ja) | Ｐａｒｐ７阻害剤及びその使用 | |
| ES2720525T3 (es) | Derivados fluorados de benzofuranil-pirimidina que contienen un grupo sulfona | |
| EA051813B1 (ru) | Пиразолопиримидиновое соединение, его фармацевтическая композиция, способ лечения и применение | |
| BR112018009880B1 (pt) | Compostos e composições farmacêuticas moduladores dos receptores de quimiocina e seus usos |